» Articles » PMID: 26226413

Peripheral Blood Biomarkers in Multiple Sclerosis

Overview
Journal Autoimmun Rev
Publisher Elsevier
Date 2015 Jul 31
PMID 26226413
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. The heterogeneity of pathophysiological processes in MS contributes to the highly variable course of the disease and unpredictable response to therapies. The major focus of the research on MS is the identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to guide patient management reliably. Because of the difficulties in obtaining spinal fluid samples and the necessity for lumbar puncture to make a diagnosis has reduced, the research of blood-based biomarkers may provide increasingly important tools for clinical practice. However, currently there are no clearly established MS blood-based biomarkers. The availability of reliable biomarkers could radically alter the management of MS at critical phases of the disease spectrum, allowing for intervention strategies that may prevent evolution to long-term neurological disability. This article provides an overview of this research field and focuses on recent advances in blood-based biomarker research.

Citing Articles

Clinical Application of Blood Biomarkers in Neurodegenerative Diseases-Present and Future Perspectives.

Krawczuk D, Kulczynska-Przybik A, Mroczko B Int J Mol Sci. 2024; 25(15).

PMID: 39125699 PMC: 11311320. DOI: 10.3390/ijms25158132.


Task-oriented exercise effects on walking and corticospinal excitability in multiple sclerosis: protocol for a randomized controlled trial.

Moslemi Z, Toledo-Aldana E, Baldwin B, Donkers S, Eng J, Mondal P BMC Sports Sci Med Rehabil. 2023; 15(1):175.

PMID: 38129896 PMC: 10734154. DOI: 10.1186/s13102-023-00790-5.


Data Mining of Microarray Datasets in Translational Neuroscience.

OConnor L, OConnor B, Zeng J, Lo C Brain Sci. 2023; 13(9).

PMID: 37759919 PMC: 10527016. DOI: 10.3390/brainsci13091318.


Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.

Wessels M, van Lierop Z, Noteboom S, Strijbis E, Heijst J, van Kempen Z Mult Scler. 2023; 29(10):1229-1239.

PMID: 37530045 PMC: 10503252. DOI: 10.1177/13524585231188625.


Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis.

Lleixa C, Caballero-Avila M, Pascual-Goni E, Martin-Aguilar L, Vidal N, Tejada C Brain Commun. 2023; 5(2):fcad109.

PMID: 37091585 PMC: 10116574. DOI: 10.1093/braincomms/fcad109.